Cargando…
Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease
Introduction: Treatment strategies in Parkinson’s disease (PD) can improve a patient’s quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981245/ https://www.ncbi.nlm.nih.gov/pubmed/29862060 http://dx.doi.org/10.3390/bs8050051 |
_version_ | 1783328006652035072 |
---|---|
author | Pedroso, Ivonne Garcia, Marité Casabona, Enrique Morales, Lilia Bringas, Maria Luisa Pérez, Leslie Rodríguez, Teresita Sosa, Ileana Ricardo, Yordanka Padrón, Arnoldo Amaro, Daniel |
author_facet | Pedroso, Ivonne Garcia, Marité Casabona, Enrique Morales, Lilia Bringas, Maria Luisa Pérez, Leslie Rodríguez, Teresita Sosa, Ileana Ricardo, Yordanka Padrón, Arnoldo Amaro, Daniel |
author_sort | Pedroso, Ivonne |
collection | PubMed |
description | Introduction: Treatment strategies in Parkinson’s disease (PD) can improve a patient’s quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin. In Cuba, the Center for Molecular Immunology (CIM) is a cutting edge scientific center where the recombinant form (EPOrh) and recombinant human erythropoietin with low sialic acid (NeuroEPO) are produced. We performed two clinical trials to evaluate the safety and tolerability of these two drugs in PD patients. In this paper we want to show the positive results of the additional cognitive tests employed, as part of the comprehensive assessment. Materials and method: Two studies were conducted in PD patients from the outpatient clinic of CIREN, including n = 10 and n = 26 patients between 60 and 66 years of age, in stages 1 to 2 of the Hoehn and Yahr Scale. The first study employed recombinant human (rhEPO) and the second an intranasal formulation of neuroEPO. All patients were evaluated with a battery of neuropsychological scales composed to evaluate global cognitive functioning, executive function, and memory. Results: The general results in both studies showed a positive response to the cognitive functions in PD patients, who were undergoing pharmacological treatment with respect to the evaluation (p < 0.05) before the intervention. Conclusions: Erythropoietin has a discrete positive effect on the cognitive functions of patients with Parkinson’s disease, which could be interpreted as an effect of the neuroprotective properties of this molecules. To confirm the results another clinical trial phase III with neuroEPO is in progress, also designed to discard any influence of a placebo effect on cognition. |
format | Online Article Text |
id | pubmed-5981245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-59812452018-06-01 Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease Pedroso, Ivonne Garcia, Marité Casabona, Enrique Morales, Lilia Bringas, Maria Luisa Pérez, Leslie Rodríguez, Teresita Sosa, Ileana Ricardo, Yordanka Padrón, Arnoldo Amaro, Daniel Behav Sci (Basel) Article Introduction: Treatment strategies in Parkinson’s disease (PD) can improve a patient’s quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin. In Cuba, the Center for Molecular Immunology (CIM) is a cutting edge scientific center where the recombinant form (EPOrh) and recombinant human erythropoietin with low sialic acid (NeuroEPO) are produced. We performed two clinical trials to evaluate the safety and tolerability of these two drugs in PD patients. In this paper we want to show the positive results of the additional cognitive tests employed, as part of the comprehensive assessment. Materials and method: Two studies were conducted in PD patients from the outpatient clinic of CIREN, including n = 10 and n = 26 patients between 60 and 66 years of age, in stages 1 to 2 of the Hoehn and Yahr Scale. The first study employed recombinant human (rhEPO) and the second an intranasal formulation of neuroEPO. All patients were evaluated with a battery of neuropsychological scales composed to evaluate global cognitive functioning, executive function, and memory. Results: The general results in both studies showed a positive response to the cognitive functions in PD patients, who were undergoing pharmacological treatment with respect to the evaluation (p < 0.05) before the intervention. Conclusions: Erythropoietin has a discrete positive effect on the cognitive functions of patients with Parkinson’s disease, which could be interpreted as an effect of the neuroprotective properties of this molecules. To confirm the results another clinical trial phase III with neuroEPO is in progress, also designed to discard any influence of a placebo effect on cognition. MDPI 2018-05-21 /pmc/articles/PMC5981245/ /pubmed/29862060 http://dx.doi.org/10.3390/bs8050051 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pedroso, Ivonne Garcia, Marité Casabona, Enrique Morales, Lilia Bringas, Maria Luisa Pérez, Leslie Rodríguez, Teresita Sosa, Ileana Ricardo, Yordanka Padrón, Arnoldo Amaro, Daniel Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease |
title | Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease |
title_full | Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease |
title_fullStr | Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease |
title_full_unstemmed | Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease |
title_short | Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease |
title_sort | protective activity of erythropoyetine in the cognition of patients with parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981245/ https://www.ncbi.nlm.nih.gov/pubmed/29862060 http://dx.doi.org/10.3390/bs8050051 |
work_keys_str_mv | AT pedrosoivonne protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT garciamarite protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT casabonaenrique protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT moraleslilia protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT bringasmarialuisa protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT perezleslie protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT rodriguezteresita protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT sosaileana protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT ricardoyordanka protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT padronarnoldo protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT amarodaniel protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease |